A Phase 3 interventional study of Octreotide capsules in Acromegaly, sponsored by Chiasma, Inc.. Completed at 53 sites in 13 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-04-22.
Sponsored by Chiasma, Inc. (part of Chiesi Farmaceutici S.p.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing octreotide in Acromegaly — 1 open to participants now, 1 under way, 1 of them phase 3. Octreotide · Acromegaly.
Among the 25 studies testing octreotide in Acromegaly, this one is the 4th largest by enrollment, is the only one that started in 2016, is one of 12 in phase 3, and was the 20th registered.
202 studies on the registry are indexed under Acromegaly; 19 are open to participants now.
Browse Acromegaly studies →1 of the 25 studies testing octreotide in Acromegaly is open now. Recruiting first, the newest first:
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Ages 18–80
Octreotide: first FDA approval 1988 (SANDOSTATIN), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 14 Acromegaly studies recruiting now, 7 (50%) set no upper age limit and 5 (36%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 146 is above the median of 43 across 115 interventional studies indexed under Acromegaly.
Median enrollment 56 across the 25 interventional studies. Of the 22 that completed or were terminated, 7 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 25 have an industry lead sponsor. The 10 most frequent:
This study is registered under Chiasma, Inc., one of the names counted as Chiesi Farmaceutici S.p.A.. Under that name alone:
Chiasma, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Chiesi Farmaceutici S.p.A. has 3 studies filed under Acromegaly — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing octreotide in Acromegaly, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Octreotide capsule is a novel, orally-administered formulation of the commercially-available injectable drug octreotide. In a recent phase 3 trial (OPTMAL; NCT03252353), oral octreotide capsules demonstrated sustained biochemical response up to 13 months in patients with acromegaly previously managed with somatostatin analog injections (ref).
The objective of this study was to compare the efficacy, safety, and patient reported outcomes (PROs) between oral octreotide capsules and injectable somatostatin receptor ligands (SRLs).
This was phase 3, randomized, open-label, active controlled, multicenter study to evaluate the maintenance of response, safety and patient reported outcomes (PROs) in acromegaly patients treated with octreotide capsules and in patients treated with standard of care parenteral somatostatin receptor ligands (SRLs), who previously tolerated and demonstrated biochemical control on both treatments.
The core study consisted of three phases: a Screening phase, Run-in phase and a Randomized Controlled Treatment (RCT) phase.
Eligible patients who were biochemically controlled on parenteral SRLs were switched to octreotide capsules for a 26-week period Run-in phase. During this phase the effective dose for each patient was determined through dose titration.
Patients whose acromegaly has been controlled biochemically on octreotide capsules at the end of the Run-in phase entered a 36-week open-label RCT phase, where they randomized to continue on octreotide capsules or switch back to their injectable SRL treatment (as received prior to Screening).
Following the completion of the core study (Screening, Run-in and RCT phases), eligible patients were offered to enter the Study Extension phase and receive octreotide capsules until product marketing or study termination.
A Sub-study, performed in selected non-European sites, allowed patients with inadequate biochemical control on octreotide capsules during the Run-in phase to enter a Combination phase and receive co-administration of octreotide capsules with cabergoline tablets for a total of 36 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral octreotide capsules
Drug: Octreotide capsules
Oral octreotide capsules
Drug: Octreotide capsules
Injectable somatostatin analogs (octreotide or lanreotide)
Drug: Octreotide capsules
Octreotide capsules plus cabergoline
Drug: Octreotide capsules
Also known as: Injection SRLs
Proportion of Patients Who Are Biochemically Controlled Throughout the RCT Phase
Proportion of patients who are biochemically controlled throughout the RCT phase. A patient was considered biochemically controlled if IGF-1 Time Weighted Average (TWA) during the RCT phase is \<1.3 ULN
Time frame: 62 weeks
Proportion of Patients With Clinical and Biochemical Control at the End of the RCT Phase
Proportion of patients with clinical and biochemical control at the end of the RCT phase. Patients were considered biochemically and clinically controlled if they met both of the following criteria: * Their IGF-1 TWA during the RCT phase was \<1.3 times ULN * Their AIS score at week 62/EOT was maintained or reduced compared to week 26 (start of RCT phase)
Time frame: Week 62/ End of treatment; EOT
Proportion of Patients Who Maintain or Reduce the Overall Number of Active Acromegaly Symptoms at the End of the RCT Phase
Proportion of patients who maintain or reduce the overall number of active acromegaly symptoms at the end of the RCT phase (week 62/ EOT) , compared to week 26 (start of the RCT phase
Time frame: 62 weeks
Proportion of Patients Who Maintain or Improve Their Overall Acromegaly Index of Severity (AIS) Score at the End of the RCT Phase
Proportion of patients who maintain or improve their overall Acromegaly index of severity (AIS) score at the end of the RCT phase (improvement defined as a reduction of at least one point in the AIS score), compared to week 26 (start of the RCT phase)
Time frame: 62 weeks
Proportion of Patients of Those Completing the RCT Phase Who Entered the Study Extension Phase
Proportion of patients of those completing the RCT phase (at a time octreotide capsules were not commercially available at the specific country), who entered the Study Extension phase, overall and by treatment group
Time frame: 62 weeks
Change in IGF-1 Levels in the RCT Phase
Change in IGF-1 levels from the start of the randomized phase to the end of RCT phase. Complete Responder (CR) is defined as IGF-1 ≤ 1 x ULN; Partial Responder (PR) is defined as 1 x ULN \< IGF-1 \< 1.3 x ULN, and Non-Responder (NR): IGF-1 ≥ 1.3 x ULN
Time frame: Change from Week 26 to week 62
Change in GH Levels in the RCT Phase
Change in GH levels from the start of the randomized phase through the end of RCT phase.
Time frame: Change from Week 26 to week 62
Proportion of Patients Reporting Injection Site Reactions in the Acro-TSQ During the RCT Phase
Proportion of patients reporting injection site reactions (ISRs). Acromegaly treatment satisfaction questionnaire (ACRO-TSQ) is a validated PRO tool assessing overall convenience and satisfaction with treatment and patient perception of symptomatic control and adverse drug. It includes 6 scales: Symptom Interference, (4 items); Treatment Convenience, (6 items); Injection Site Interference (2 items); GI Interference (3 items); Treatment Satisfaction, (3 items); and Emotional Reaction (3 items). Each scale score can range from 0 to 100, with 0 representing the lowest (highest burden/lower satisfaction) and 100 representing the best possible score (lowest burden/highest satisfaction) for each of the 6 scales. Positive ACRO-TSQ change scores indicate improvement while negative change scores indicate worsening.
Time frame: 62 weeks
Proportion of Patients Reporting Interference With Daily Activities in Acro-TSQ During the RCT Phase
Proportion of patients reporting interference with daily activities in the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) during the RCT phase. Acro-TSQ is a validated PRO tool assessing overall convenience and satisfaction with treatment and patient perception of symptomatic control and adverse drug. It includes 6 scales: Symptom Interference, (4 items); Treatment Convenience, (6 items); Injection Site Interference (2 items); GI Interference (3 items); Treatment Satisfaction, (3 items); and Emotional Reaction (3 items). Each scale score can range from 0 to 100, with 0 representing the lowest (highest burden/lower satisfaction) and 100 representing the best possible score (lowest burden/highest satisfaction) for each of the 6 scales. Positive Acro-TSQ change scores indicate improvement while negative change scores indicate worsening.
Time frame: 62 weeks
Proportion of Patients on Octreotide Capsules Who Are Biochemically Controlled at the End of the RCT Phase- Landmark Analysis
Proportion of patients on octreotide capsules who are biochemically controlled at the end of the RCT phase defined as IGF-1\< 1.3 x ULN based on average of weeks 58 and 62
Time frame: Average of weeks 58 and 62
Proportion of Week 26 Responders on Octreotide Capsules Who Are Biochemically Controlled at the End of the RCT Phase- Landmark Sensitivity Analysis
Proportion of patients on Octreotide Capsules Who Are Biochemically Controlled at the End of the RCT Phase- Landmark sensitivity analysis- Week 26 responders
Time frame: 62 weeks
Proportion of Patients Biochemically Controlled at the End of Run-in
Proportion of patients biochemically controlled at the end of the Run-in phase, defined as average IGF-1 levels during weeks 24 and 26 \< 1.3xULN
Time frame: 26 weeks
Proportion of Patients With a Reduction in the Overall Number of Active Acromegaly Symptoms at the End of the Run-in Phase
Proportion of patients with a reduction in the overall number of active acromegaly symptoms at the end of the Run-in phase compared to Baseline
Time frame: 26 weeks
Proportion of Patients With Improved Acromegaly Index of Severity (AIS) Score at the End of the Run-in Phase
Proportion of patients with improved AIS score at the end of the Run-in phase compared to Baseline Acromegaly index of severity (AIS) at the end of Run-in phase compared to Baseline. The Acromegaly Index of Severity (AIS) symptom score is calculated based on the presence and severity of 5 acromegaly signs/symptoms: headache, swelling of extremities, joint pain, sweating, and fatigue. Each symptom was graded from no symptoms (score 0), to mild symptoms (1), moderate (2), or severe symptoms (3).
Time frame: 26 weeks
EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L) Index Scores During the Run-in Phase
Change from baselines in EQ-5D-5L Index scores in randomized participants during the Run-in phase. EQ-5D-5L (five severity levels EQ-5D) is a standardized instrument completed by the patient for use as a measure of health outcome applicable to a wide range of health conditions. It comprises 5 dimensions of health: mobility, ability to self care, ability to undertake usual activities, pain and discomfort, and anxiety and depression. Based on qualitative and quantitative studies conducted by the EuroQol Group, there are 5 levels under each domain: 'no problems' (assigned a value of 1), 'slight problems' (assigned a value of 2), 'moderate problems' (assigned a value of 3), 'severe problems' (assigned a value of 4), and 'unable to/extreme problems' (assigned a value of 5). An EQ-5D Index score is calculated based on the responses to these 5 dimensions of health. Weights for use in the index calculation are not universally available. Higher values represent better health states.
Time frame: 26 weeks
Change From Baseline to End of RCT Phase in WPAI
Work Productivity and Activity Impairment Questionnaire- RCT phase. WPAI:SHP is a standardized and validated PRO questionnaire to measure health outcomes in clinical trial settings. It measures time missed from work, impairment of work and regular activities due to overall health and symptoms, relative to measures of general health perceptions, role (physical), role (emotional), pain, symptom severity, and global measures of work and interference with regular activity. The WPAI yields 4 types of scores: (1) absenteeism (work time missed); (2) presenteeism (impairment at work/reduced on-the-job effectiveness); (3) work productivity loss (overall work impairment/absenteeism plus presenteeism); and (4) activity impairment. Each of the 4 WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity (i.e., worse outcomes).
Time frame: 26 weeks
Change From Baseline to End of Run-in Phase in WPAI
Work Productivity and Activity Impairment Questionnaire- Run-in phase. WPAI:SHP is a standardized and validated PRO questionnaire to measure health outcomes in clinical trial settings. It measures time missed from work, impairment of work and regular activities due to overall health and symptoms, relative to measures of general health perceptions, role (physical), role (emotional), pain, symptom severity, and global measures of work and interference with regular activity. The WPAI yields 4 types of scores: (1) absenteeism (work time missed); (2) presenteeism (impairment at work/reduced on-the-job effectiveness); (3) work productivity loss (overall work impairment/absenteeism plus presenteeism); and (4) activity impairment. Each of the 4 WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity (i.e., worse outcomes).
Time frame: 62 weeks
Change in Acromegaly Treatment Satisfaction Questionnaire (ACRO-TSQ) Scores From Baseline to End of Run-in in Randomized Patients.
Change in Acromegaly treatment satisfaction questionnaire (ACRO-TSQ) PRO questionnaire from baseline to end of Run-in phase in randomized patients. Acro-TSQ is a validated PRO tool assessing overall convenience and satisfaction with treatment and patient perception of symptomatic control and adverse drug. It includes 6 scales: Symptom Interference, (4 items); Treatment Convenience, (6 items); Injection Site Interference (2 items); GI Interference (3 items); Treatment Satisfaction, (3 items); and Emotional Reaction (3 items). Each scale score can range from 0 to 100, with 0 representing the lowest (highest burden/lower satisfaction) and 100 representing the best possible score (lowest burden/highest satisfaction) for each of the 6 scales. Positive Acro-TSQ change scores indicate improvement while negative change scores indicate worsening.
Time frame: 26 weeks
146 patients were enrolled into the Run-in phase. A total of 116 patients completed the Run-in phase and 30 patients discontinued the Run in phase. Of the 116 patients who completed the Run-in phase, 92 patients with IGF-1\<1.3 ULN entered the RCT phase, 11 patients with IGF-1≥1.3 and \<2 ULN on the highest octreotide dose entered the Combination phase, and 13 patients did not continue treatment.
| Milestone | Run-in Phase | RCT Phase - Oral | RCT Phase - Injectables | Combination Phase (Sub-study) |
|---|---|---|---|---|
| Started | 146 | 0 | 0 | 0 |
| Completed | 116 | 0 | 0 | 0 |
| Not completed | 30 | 0 | 0 | 0 |
| Milestone | Run-in Phase | RCT Phase - Oral | RCT Phase - Injectables | Combination Phase (Sub-study) |
|---|---|---|---|---|
| Started | 0 | 55 | 37 | 0 |
| Completed | 0 | 54 | 35 | 0 |
| Not completed | 0 | 1 | 2 | 0 |
| Milestone | Run-in Phase | RCT Phase - Oral | RCT Phase - Injectables | Combination Phase (Sub-study) |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 14 |
| Completed | 0 | 0 | 0 | 8 |
| Not completed | 0 | 0 | 0 | 6 |
Proportion of patients who are biochemically controlled throughout the RCT phase. A patient was considered biochemically controlled if IGF-1 Time Weighted Average (TWA) during the RCT phase is \<1.3 ULN
| Participants | RCT Phase - Oral | RCT Phase - Injectables |
|---|---|---|
| Proportion of Patients Who Are Biochemically Controlled Throughout the RCT Phase | 50 | 37 |
Proportion of patients with clinical and biochemical control at the end of the RCT phase. Patients were considered biochemically and clinically controlled if they met both of the following criteria: * Their IGF-1 TWA during the RCT phase was \<1.3 times ULN * Their AIS score at week 62/EOT was maintained or reduced compared to week 26 (start of RCT phase)
| Participants | RCT Phase - Oral | RCT Phase - Injectables |
|---|---|---|
| Proportion of Patients With Clinical and Biochemical Control at the End of the RCT Phase | 36 | 27 |
Proportion of patients who maintain or reduce the overall number of active acromegaly symptoms at the end of the RCT phase (week 62/ EOT) , compared to week 26 (start of the RCT phase
| Participants | RCT Phase - Oral | RCT Phase - Injectables |
|---|---|---|
| Proportion of Patients Who Maintain or Reduce the Overall Number of Active Acromegaly Symptoms at the End of the RCT Phase | 41 | 26 |
Proportion of patients who maintain or improve their overall Acromegaly index of severity (AIS) score at the end of the RCT phase (improvement defined as a reduction of at least one point in the AIS score), compared to week 26 (start of the RCT phase)
| Participants | RCT Phase - Oral | RCT Phase - Injectables |
|---|---|---|
| Proportion of Patients Who Maintain or Improve Their Overall Acromegaly Index of Severity (AIS) Score at the End of the RCT Phase | 40 | 25 |
Proportion of patients of those completing the RCT phase (at a time octreotide capsules were not commercially available at the specific country), who entered the Study Extension phase, overall and by treatment group
| Participants | RCT Phase - Oral | RCT Phase - Injectables |
|---|---|---|
| Proportion of Patients of Those Completing the RCT Phase Who Entered the Study Extension Phase | 34 | 18 |
Change in IGF-1 levels from the start of the randomized phase to the end of RCT phase. Complete Responder (CR) is defined as IGF-1 ≤ 1 x ULN; Partial Responder (PR) is defined as 1 x ULN \< IGF-1 \< 1.3 x ULN, and Non-Responder (NR): IGF-1 ≥ 1.3 x ULN
| x Upper limit of normal ("ULN") | RCT Phase - Oral | RCT Phase - Injectables |
|---|---|---|
| Change in IGF-1 Levels in the RCT Phase | -0.01 ± 0.199 | -0.04 ± 0.133 |
Change in GH levels from the start of the randomized phase through the end of RCT phase.
| ng/mL | RCT Phase - Oral | RCT Phase - Injectables |
|---|---|---|
| Change in GH Levels in the RCT Phase | -0.02 ± 0.506 | 0.27 ± 1.219 |
Proportion of patients reporting injection site reactions (ISRs). Acromegaly treatment satisfaction questionnaire (ACRO-TSQ) is a validated PRO tool assessing overall convenience and satisfaction with treatment and patient perception of symptomatic control and adverse drug. It includes 6 scales: Symptom Interference, (4 items); Treatment Convenience, (6 items); Injection Site Interference (2 items); GI Interference (3 items); Treatment Satisfaction, (3 items); and Emotional Reaction (3 items). Each scale score can range from 0 to 100, with 0 representing the lowest (highest burden/lower satisfaction) and 100 representing the best possible score (lowest burden/highest satisfaction) for each of the 6 scales. Positive ACRO-TSQ change scores indicate improvement while negative change scores indicate worsening.
| Participants | RCT Phase - Oral | RCT Phase - Injectables |
|---|---|---|
| Proportion of Patients Reporting Injection Site Reactions in the Acro-TSQ During the RCT Phase | 0 | 17 |
Proportion of patients reporting interference with daily activities in the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) during the RCT phase. Acro-TSQ is a validated PRO tool assessing overall convenience and satisfaction with treatment and patient perception of symptomatic control and adverse drug. It includes 6 scales: Symptom Interference, (4 items); Treatment Convenience, (6 items); Injection Site Interference (2 items); GI Interference (3 items); Treatment Satisfaction, (3 items); and Emotional Reaction (3 items). Each scale score can range from 0 to 100, with 0 representing the lowest (highest burden/lower satisfaction) and 100 representing the best possible score (lowest burden/highest satisfaction) for each of the 6 scales. Positive Acro-TSQ change scores indicate improvement while negative change scores indicate worsening.
| Participants | RCT Phase - Oral | RCT Phase - Injectables |
|---|---|---|
| Proportion of Patients Reporting Interference With Daily Activities in Acro-TSQ During the RCT Phase | 0 | 13 |
Proportion of patients on octreotide capsules who are biochemically controlled at the end of the RCT phase defined as IGF-1\< 1.3 x ULN based on average of weeks 58 and 62
| Participants | RCT Phase - Oral | RCT Phase - Injectables |
|---|---|---|
| Proportion of Patients on Octreotide Capsules Who Are Biochemically Controlled at the End of the RCT Phase- Landmark Analysis | 49 | 35 |
Proportion of patients on Octreotide Capsules Who Are Biochemically Controlled at the End of the RCT Phase- Landmark sensitivity analysis- Week 26 responders
| Participants | RCT Phase - Oral | RCT Phase - Injectables |
|---|---|---|
| Proportion of Week 26 Responders on Octreotide Capsules Who Are Biochemically Controlled at the End of the RCT Phase- Landmark Sensitivity Analysis | 45 | 34 |
Proportion of patients biochemically controlled at the end of the Run-in phase, defined as average IGF-1 levels during weeks 24 and 26 \< 1.3xULN
| Participants | Run-in Phase |
|---|---|
| Proportion of Patients Biochemically Controlled at the End of Run-in | 94 |
Proportion of patients with a reduction in the overall number of active acromegaly symptoms at the end of the Run-in phase compared to Baseline
| Participants | Run-in Phase |
|---|---|
| Proportion of Patients With a Reduction in the Overall Number of Active Acromegaly Symptoms at the End of the Run-in Phase | 97 |
Proportion of patients with improved AIS score at the end of the Run-in phase compared to Baseline Acromegaly index of severity (AIS) at the end of Run-in phase compared to Baseline. The Acromegaly Index of Severity (AIS) symptom score is calculated based on the presence and severity of 5 acromegaly signs/symptoms: headache, swelling of extremities, joint pain, sweating, and fatigue. Each symptom was graded from no symptoms (score 0), to mild symptoms (1), moderate (2), or severe symptoms (3).
| Participants | Run-in Phase |
|---|---|
| Proportion of Patients With Improved Acromegaly Index of Severity (AIS) Score at the End of the Run-in Phase | 45 |
Change from baselines in EQ-5D-5L Index scores in randomized participants during the Run-in phase. EQ-5D-5L (five severity levels EQ-5D) is a standardized instrument completed by the patient for use as a measure of health outcome applicable to a wide range of health conditions. It comprises 5 dimensions of health: mobility, ability to self care, ability to undertake usual activities, pain and discomfort, and anxiety and depression. Based on qualitative and quantitative studies conducted by the EuroQol Group, there are 5 levels under each domain: 'no problems' (assigned a value of 1), 'slight problems' (assigned a value of 2), 'moderate problems' (assigned a value of 3), 'severe problems' (assigned a value of 4), and 'unable to/extreme problems' (assigned a value of 5). An EQ-5D Index score is calculated based on the responses to these 5 dimensions of health. Weights for use in the index calculation are not universally available. Higher values represent better health states.
| units on a scale | Run-in Phase |
|---|---|
| EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L) Index Scores During the Run-in Phase | 0.0433 (0.011 to 0.0755) |
Work Productivity and Activity Impairment Questionnaire- RCT phase. WPAI:SHP is a standardized and validated PRO questionnaire to measure health outcomes in clinical trial settings. It measures time missed from work, impairment of work and regular activities due to overall health and symptoms, relative to measures of general health perceptions, role (physical), role (emotional), pain, symptom severity, and global measures of work and interference with regular activity. The WPAI yields 4 types of scores: (1) absenteeism (work time missed); (2) presenteeism (impairment at work/reduced on-the-job effectiveness); (3) work productivity loss (overall work impairment/absenteeism plus presenteeism); and (4) activity impairment. Each of the 4 WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity (i.e., worse outcomes).
| Percentage change from Baseline RCT | RCT Phase - Oral | RCT Phase - Injectables |
|---|---|---|
| Absenteeism (%) | -0.34 (-2.11 to 1.43) | 0.79 (-1.53 to 3.12) |
| Presenteeism (%) | 1.85 (-4.48 to 8.17) | 5.98 (-2.02 to 13.98) |
| Work productivity loss (%) | 1.49 (-5.09 to 8.08) | 6.93 (-1.74 to 15.59) |
| Activity impairment (%) | 0.84 (-4.34 to 6.02) | 4.34 (-2.1 to 10.77) |
Work Productivity and Activity Impairment Questionnaire- Run-in phase. WPAI:SHP is a standardized and validated PRO questionnaire to measure health outcomes in clinical trial settings. It measures time missed from work, impairment of work and regular activities due to overall health and symptoms, relative to measures of general health perceptions, role (physical), role (emotional), pain, symptom severity, and global measures of work and interference with regular activity. The WPAI yields 4 types of scores: (1) absenteeism (work time missed); (2) presenteeism (impairment at work/reduced on-the-job effectiveness); (3) work productivity loss (overall work impairment/absenteeism plus presenteeism); and (4) activity impairment. Each of the 4 WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity (i.e., worse outcomes).
| Percentage change from Run-in baseline | Run-in Phase |
|---|---|
| Absenteeism (%) | -0.81 (-3.84 to 2.21) |
| Presenteeism (%) | -6.65 (-12.39 to -0.9) |
| Work Productivity Loss (%) | -6.92 (-12.83 to -1.02) |
| Activity Impairment (%) | -4.94 (-9.17 to -0.71) |
Change in Acromegaly treatment satisfaction questionnaire (ACRO-TSQ) PRO questionnaire from baseline to end of Run-in phase in randomized patients. Acro-TSQ is a validated PRO tool assessing overall convenience and satisfaction with treatment and patient perception of symptomatic control and adverse drug. It includes 6 scales: Symptom Interference, (4 items); Treatment Convenience, (6 items); Injection Site Interference (2 items); GI Interference (3 items); Treatment Satisfaction, (3 items); and Emotional Reaction (3 items). Each scale score can range from 0 to 100, with 0 representing the lowest (highest burden/lower satisfaction) and 100 representing the best possible score (lowest burden/highest satisfaction) for each of the 6 scales. Positive Acro-TSQ change scores indicate improvement while negative change scores indicate worsening.
| score on a scale | Run-in Phase |
|---|---|
| Emotional reaction - Change from baseline | 9.65 (3.31 to 15.98) |
| GI interference - Change from baseline | 4.24 (-1.32 to 9.8) |
| Symptom interference- Change from baseline | 2.45 (-2.1 to 7) |
| Treatment convenience - Change from baseline | 6.37 (0.25 to 12.5) |
| Treatment satisfaction - Change from baseline | 6.73 (0.9 to 12.55) |
Collected over 1 year, 3 months for both the Run-in and RCT phases.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Run-in Phase | 0/146 (0%) | 6/146 (4.1%) | 106/146 (72.6%) |
| RCT Phase - Oral | 1/55 (1.8%) | 3/55 (5.5%) | 39/55 (70.9%) |
| RCT Phase - Injectables | 0/37 (0%) | 3/37 (8.1%) | 26/37 (70.3%) |
| Combination Phase (Sub-study) | 0/14 (0%) | 0/14 (0%) | 11/14 (78.6%) |
| Event | Run-in Phase | RCT Phase - Oral | RCT Phase - Injectables | Combination Phase (Sub-study) |
|---|---|---|---|---|
| Acute myocardial infarctionCardiac disorders | 0/146 | 1/55 | 1/37 | 0/14 |
| Sinus bradycardiaCardiac disorders | 0/146 | 0/55 | 1/37 | 0/14 |
| CholelithiasisHepatobiliary disorders | 0/146 | 0/55 | 1/37 | 0/14 |
| PericarditisCardiac disorders | 0/146 | 1/55 | 0/37 | 0/14 |
| Toxicity to various agentsInjury, poisoning and procedural complications | 0/146 | 1/55 | 0/37 | 0/14 |
| Atrial flutterCardiac disorders | 1/146 | 0/55 | 0/37 | 0/14 |
| Cardiac failureCardiac disorders | 1/146 | 0/55 | 0/37 | 0/14 |
| Cardiac failure congestiveCardiac disorders | 1/146 | 0/55 | 0/37 | 0/14 |
| Cholecystitis acuteHepatobiliary disorders | 1/146 | 0/55 | 0/37 | 0/14 |
| Post cholecystectomy syndromeHepatobiliary disorders | 1/146 | 0/55 | 0/37 | 0/14 |
| Event | Run-in Phase | RCT Phase - Oral | RCT Phase - Injectables | Combination Phase (Sub-study) |
|---|---|---|---|---|
| FlatulenceGastrointestinal disorders | 14/146 | 14/55 | 8/37 | 1/14 |
| NauseaGastrointestinal disorders | 32/146 | 11/55 | 3/37 | 2/14 |
| DiarrheaGastrointestinal disorders | 22/146 | 6/55 | 5/37 | 1/14 |
| ConstipationGastrointestinal disorders | 5/146 | 3/55 | 5/37 | 0/14 |
| Injection site noduleGeneral disorders | 0/146 | 0/55 | 5/37 | 0/14 |
| HeadacheNervous system disorders | 18/146 | 5/55 | 1/37 | 0/14 |
| ErythemaSkin and subcutaneous tissue disorders | 0/146 | 0/55 | 4/37 | 0/14 |
| Abdominal painGastrointestinal disorders | 13/146 | 5/55 | 3/37 | 0/14 |
| NasopharyngitisInfections and infestations | 9/146 | 5/55 | 0/37 | 1/14 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 6/146 | 5/55 | 2/37 | 0/14 |
Acromegaly patients who previously tolerated and demonstrated a biochemical control on SRLs
| Age, Categorical(Participants) | Run-in Phase | RCT Phase - Oral | RCT Phase - Injectables | Combination Phase (Sub-study) | Total |
|---|---|---|---|---|---|
| Run-in phase — <=18 years | 0 | 0 | 0 | 0 | 0 |
| Run-in phase — Between 18 and 65 years | 124 | 0 | 0 | 0 | 124 |
| Run-in phase — >=65 years | 22 | 0 | 0 | 0 | 22 |
| RCT phase — <=18 years | 0 | 0 | 0 | 0 | 0 |
| RCT phase — Between 18 and 65 years | 0 | 46 | 32 | 0 | 78 |
| RCT phase — >=65 years | 0 | 9 | 5 | 0 | 14 |
| Combination Phase — <=18 years | 0 | 0 | 0 | 0 | 0 |
| Combination Phase — Between 18 and 65 years | 0 | 0 | 0 | 11 | 11 |
| Combination Phase — >=65 years | 0 | 0 | 0 | 3 | 3 |
| Age, Continuous(years) | Run-in Phase | RCT Phase - Oral | RCT Phase - Injectables | Combination Phase (Sub-study) | Total |
|---|---|---|---|---|---|
| Run-in phase | 54.1 ± 10.5 | — | — | — | 54.1 ± 10.5 |
| RCT phase | — | 54.1 ± 10.88 | 55.2 ± 8.78 | — | 54.5 ± 10.05 |
| Combination phase | — | — | — | 59.8 ± 5.82 | 59.8 ± 5.82 |
| Sex: Female, Male(Participants) | Run-in Phase | RCT Phase - Oral | RCT Phase - Injectables | Combination Phase (Sub-study) | Total |
|---|---|---|---|---|---|
| Run-in phase — Female | 94 | 0 | 0 | 0 | 94 |
| Run-in phase — Male | 52 | 0 | 0 | 0 | 52 |
| RCT phase — Female | 0 | 35 | 26 | 0 | 61 |
| RCT phase — Male | 0 | 20 | 11 | 0 | 31 |
| Combination phase — Female | 0 | 0 | 0 | 10 | 10 |
| Combination phase — Male | 0 | 0 | 0 | 4 | 4 |
| Ethnicity (NIH/OMB)(Participants) | Run-in Phase | RCT Phase - Oral | RCT Phase - Injectables | Combination Phase (Sub-study) | Total |
|---|---|---|---|---|---|
| Run-in phase — Hispanic or Latino | 5 | 0 | 0 | 0 | 5 |
| Run-in phase — Not Hispanic or Latino | 130 | 0 | 0 | 0 | 130 |
| Run-in phase — Unknown or Not Reported | 11 | 0 | 0 | 0 | 11 |
| RCT phase — Hispanic or Latino | 0 | 1 | 2 | 0 | 3 |
| RCT phase — Not Hispanic or Latino | 0 | 50 | 33 | 0 | 83 |
| RCT phase — Unknown or Not Reported | 0 | 4 | 2 | 0 | 6 |
| Combination phase — Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Combination phase — Not Hispanic or Latino | 0 | 0 | 0 | 14 | 14 |
| Combination phase — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Run-in Phase | RCT Phase - Oral | RCT Phase - Injectables | Combination Phase (Sub-study) | Total |
|---|---|---|---|---|---|
| Run-in phase — American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Run-in phase — Asian | 1 | 0 | 0 | 0 | 1 |
| Run-in phase — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Run-in phase — Black or African American | 3 | 0 | 0 | 0 | 3 |
| Run-in phase — White | 133 | 0 | 0 | 0 | 133 |
| Run-in phase — More than one race | 9 | 0 | 0 | 0 | 9 |
| Run-in phase — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| RCT phase — American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| RCT phase — Asian | 0 | 0 | 0 | 0 | 0 |
| RCT phase — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| RCT phase — Black or African American | 0 | 2 | 0 | 0 | 2 |
| RCT phase — White | 0 | 49 | 35 | 0 | 84 |
| RCT phase — More than one race | 0 | 4 | 2 | 0 | 6 |
| RCT phase — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Combination phase — American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Combination phase — Asian | 0 | 0 | 0 | 0 | 0 |
| Combination phase — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Combination phase — Black or African American | 0 | 0 | 0 | 0 | 0 |
| Combination phase — White | 0 | 0 | 0 | 14 | 14 |
| Combination phase — More than one race | 0 | 0 | 0 | 0 | 0 |
| Combination phase — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Run-in Phase | RCT Phase - Oral | RCT Phase - Injectables | Combination Phase (Sub-study) | Total |
|---|---|---|---|---|---|
| Hungary | 3 | — | — | — | 3 |
| United States | 37 | — | — | — | 37 |
| Spain | 6 | — | — | — | 6 |
| Russia | 65 | — | — | — | 65 |
| Austria | 6 | — | — | — | 6 |
| Italy | 2 | — | — | — | 2 |
| France | 10 | — | — | — | 10 |
| Lithuania | 8 | — | — | — | 8 |
| Serbia | 8 | — | — | — | 8 |
| Germany | 1 | — | — | — | 1 |
| Region of Enrollment(Participants) | Run-in Phase | RCT Phase - Oral | RCT Phase - Injectables | Combination Phase (Sub-study) | Total |
|---|---|---|---|---|---|
| Hungary | — | 1 | 1 | — | 2 |
| United States | — | 14 | 10 | — | 24 |
| Spain | — | 1 | 3 | — | 4 |
| Russia | — | 24 | 18 | — | 42 |
| Austria | — | 5 | 0 | — | 5 |
| Italy | — | 1 | 0 | — | 1 |
| France | — | 4 | 2 | — | 6 |
| Lithuania | — | 1 | 1 | — | 2 |
| Serbia | — | 4 | 2 | — | 6 |
| Region of Enrollment(Participants) | Run-in Phase | RCT Phase - Oral | RCT Phase - Injectables | Combination Phase (Sub-study) | Total |
|---|---|---|---|---|---|
| United States | — | — | — | 3 | 3 |
| Russia | — | — | — | 10 | 10 |
| Serbia | — | — | — | 1 | 1 |
4 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2016 to primary completion in Oct 2020, 56 months.
Results were first posted in Apr 2022, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Octreotide